With all the focus on Ramin’s statement that Unilife would not...

With all the focus on Ramin’s statement that Unilife would not breakeven until 2018 to 2020 I wanted to present an example how little that can mean to the stock price. There are many metrics that can be used to analyze  a company, but I assume that in the end most are concerned with the long term sustainability of the company and the stock price.

Insulet is focused on diabetes and insulin management through the use of it’s insulin pumps.  The range of their products compared to Unilifes is very limited. There are many differences between Insulet and Unilife including the COG and SG&A and I believe that once we begin significant shipments, execution of our long term contracts, our revenue will grow even faster than Insulet’s did.

Below is a 5 year summary of key metrics for Insulet (PODD on the NASDAQ):
2009    2010    2011    2012    2013
Revenue 66    97    152 211 247
COG    48    53    89    125 140
Gross Income 18    44    63    86    108
SG&A   N/A 78    100 122 124
Interest 13    23    13    16    17
Net LOSS 72    61    57    52    45
Stock Prices On Jan 1 7.84 15.03 16.07 19.06 21.49

All figures are in millions of USD except Stock Price.
On Jan1 2014 stock price was $35.83 current price is $45.83
Once we begin to actually show sales revenue I think we will see similar or greater share price growth.